mon-te-LOO-kast
Therapeutic Classification: allergy, cold and cough remedies, bronchodilators
Pharmacologic Classification: leukotriene antagonists
REMS
Absorption: Rapidly absorbed (63–73%) following oral administration.
Distribution: Minimally distributed to tissues.
Protein Binding: 99%.
Half-Life: 2.7–5.5 hr.
(improved symptoms of asthma)
| ROUTE | ONSET | PEAK‡ | DURATION |
|---|---|---|---|
| PO (swallow) | within 24 hr | 3–4 hr | 24 hr |
| PO (chew) | within 24 hr | 2–2.5 hr | 24 hr |
‡Plasma concentrations.
Contraindicated in:
Use Cautiously in:
Derm: rash, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS
EENT: epistaxis, otitis (children), rhinorrhea, sinusitis (children)
GI: ↑liver enzymes, abdominal pain, diarrhea (children), dyspepsia, nausea (children)
Neuro: aggression, agitation, anxiety, attention disturbance, depression, disorientation, dream abnormalities, fatigue, hallucinations, headache, insomnia, irritability, memory impairment, obsessive-compulsive symptoms, restlessness, sleep walking, stuttering, SUICIDAL BEHAVIORS/THOUGHTS, tics, tremor, weakness
Resp: cough
Misc: EOSINOPHILIC CONDITIONS (INCLUDING CHURG-STRAUSS SYNDROME), fever
Drug-drug:
Asthma
Exercise-Induced Bronchoconstriction
Allergic Rhinitis
Lab Test Considerations:
NDC Code
